{"product_id":"mrk-business-model-canvas","title":"Merck \u0026 Co., Inc. (MRK): Business Model Canvas [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Business Model Canvas of Merck \u0026amp; Co., Inc. gives you a clear, research-based view of how a \u003cstrong\u003e75,000-person\u003c\/strong\u003e global pharmaceutical company creates value through late-stage drug R\u0026amp;D, clinical trials, regulatory filings, manufacturing, and deal-making, while partnering with Mayo Clinic, Moderna, Daiichi Sankyo, NVIDIA, and biotechnology targets. You'll quickly see how it reaches oncology patients, hospitals, governments, and animal health buyers; how it sells through sales forces, specialty pharmacies, public-sector channels, and distributors; and how it earns through prescription medicines, vaccines, animal health, and licensing while managing heavy R\u0026amp;D, trial, supply chain, commercial, and acquisition costs.\u003c\/p\u003e\u003ch2\u003eMerck \u0026amp; Co., Inc. - Canvas Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eModerna V940 cancer vaccine partnership:\u003c\/strong\u003e \u003cstrong\u003e$250 million\u003c\/strong\u003e upfront payment, up to \u003cstrong\u003e$200 million\u003c\/strong\u003e in milestones, and a \u003cstrong\u003e50\/50\u003c\/strong\u003e split of development, manufacturing, and commercialization costs and profits. That structure makes the partnership a core external-innovation vehicle in Merck \u0026amp; Co., Inc.'s oncology model.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eMayo Clinic AI collaboration\u003c\/strong\u003e and \u003cstrong\u003eNVIDIA KERMIT drug-discovery model\u003c\/strong\u003e are strategic capability partnerships with no publicly disclosed cash terms in the material available here. Their value is in access to clinical expertise, data, and AI compute rather than in an upfront purchase price.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnership\u003c\/td\u003e\n\u003ctd\u003eDisclosed numbers\u003c\/td\u003e\n\u003ctd\u003eStructure\u003c\/td\u003e\n\u003ctd\u003eBusiness-model role\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMayo Clinic AI collaboration\u003c\/td\u003e\n\u003ctd\u003eNo disclosed cash value\u003c\/td\u003e\n\u003ctd\u003eClinical AI collaboration\u003c\/td\u003e\n\u003ctd\u003eValidation, data, and physician insight\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eModerna V940 cancer vaccine partnership\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$250 million\u003c\/strong\u003e, \u003cstrong\u003e$200 million\u003c\/strong\u003e, \u003cstrong\u003e50\/50\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eCo-development and co-commercialization\u003c\/td\u003e\n\u003ctd\u003eOncology pipeline expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDaiichi Sankyo ADC collaborations\u003c\/td\u003e\n\u003ctd\u003eNo disclosed cash value in the material available here\u003c\/td\u003e\n \u003ctd\u003eADC development collaboration\u003c\/td\u003e\n\u003ctd\u003eNext-generation oncology assets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNVIDIA KERMIT drug-discovery model\u003c\/td\u003e\n\u003ctd\u003eNo disclosed cash value\u003c\/td\u003e\n\u003ctd\u003eAI drug-discovery partnership\u003c\/td\u003e\n\u003ctd\u003eFaster target and molecule design\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotechnology acquisition targets\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$11.5 billion\u003c\/strong\u003e, \u003cstrong\u003e$10.8 billion\u003c\/strong\u003e, \u003cstrong\u003e$1.35 billion\u003c\/strong\u003e, \u003cstrong\u003e$1.3 billion\u003c\/strong\u003e, \u003cstrong\u003e$1.7 billion\u003c\/strong\u003e, \u003cstrong\u003e$680 million\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eAcquisition-led pipeline building\u003c\/td\u003e\n\u003ctd\u003eOwn the asset instead of licensing it\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eDaiichi Sankyo ADC collaborations\u003c\/strong\u003e matter because antibody-drug conjugates combine a monoclonal antibody with a cytotoxic payload, which lets Company Name aim for targeted cancer killing. The strategic logic is simple: if a partner already has ADC chemistry, linker technology, or payload expertise, Company Name can shorten development time versus building each piece internally.\u003c\/p\u003e\n\n\u003cp\u003eThe partnership pattern also shows up in Merck \u0026amp; Co., Inc.'s external pipeline buildout through biotechnology acquisitions. The deal values below show how much Company Name has been willing to pay for pipeline access and platform science:\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$11.5 billion\u003c\/strong\u003e for Acceleron Pharmaceuticals\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$10.8 billion\u003c\/strong\u003e for Prometheus Biosciences\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$1.35 billion\u003c\/strong\u003e for Imago BioSciences\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$1.3 billion\u003c\/strong\u003e upfront for EyeBio\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$1.7 billion\u003c\/strong\u003e in potential milestones for EyeBio\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$680 million\u003c\/strong\u003e for Harpoon Therapeutics\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThose numbers show a clear pattern: when Company Name wants control over a platform or late-stage asset, it uses multibillion-dollar M\u0026amp;A; when it wants shared risk on a single program, it uses partnership economics such as \u003cstrong\u003e$250 million\u003c\/strong\u003e upfront and \u003cstrong\u003e50\/50\u003c\/strong\u003e cost sharing.\u003c\/p\u003e\n\n\u003cp\u003eThe Mayo Clinic AI link and the NVIDIA KERMIT model fit the same logic from a different angle. They lower scientific uncertainty before Merck \u0026amp; Co., Inc. commits a larger amount such as \u003cstrong\u003e$1.35 billion\u003c\/strong\u003e, \u003cstrong\u003e$10.8 billion\u003c\/strong\u003e, or \u003cstrong\u003e$11.5 billion\u003c\/strong\u003e in an acquisition.\u003c\/p\u003e\n\n\u003cp\u003eFrom a Business Model Canvas view, these partnerships sit in the Key Partnerships block because they support three numbers-driven priorities: reduce internal R\u0026amp;D risk, share cost on high-upside programs, and keep pipeline replacement flowing through assets that can be bought, licensed, or co-developed.\u003c\/p\u003e\u003ch2\u003eMerck \u0026amp; Co., Inc. - Canvas Business Model: Key Activities\u003c\/h2\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. spent \u003cstrong\u003e$17.9B\u003c\/strong\u003e on R\u0026amp;D in 2024 against \u003cstrong\u003e$64.2B\u003c\/strong\u003e in revenue, which equals \u003cstrong\u003e27.9%\u003c\/strong\u003e of sales. The company's key activities are late-stage drug R\u0026amp;D, clinical trial execution, regulatory filings, global manufacturing and supply, and business development and M\u0026amp;A.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey activity\u003c\/td\u003e\n\u003ctd\u003eReal-life number\u003c\/td\u003e\n\u003ctd\u003eBusiness model role\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$64.2B\u003c\/td\u003e\n\u003ctd\u003eFunding base for pipeline and launches\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 R\u0026amp;D expense\u003c\/td\u003e\n\u003ctd\u003e$17.9B\u003c\/td\u003e\n\u003ctd\u003eMain internal investment engine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D as a share of revenue\u003c\/td\u003e\n\u003ctd\u003e27.9%\u003c\/td\u003e\n\u003ctd\u003eCapital intensity of the model\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. approvals in 2024\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003ctd\u003ePipeline conversion into commercial assets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eLate-stage drug R\u0026amp;D\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. keeps a large share of capital inside late-stage programs rather than only early discovery. The \u003cstrong\u003e$17.9B\u003c\/strong\u003e R\u0026amp;D bill in 2024 shows spending on phase 2\/3 development, formulation work, toxicology, scale-up, and label-expansion programs. Compared with \u003cstrong\u003e$64.2B\u003c\/strong\u003e in sales, the \u003cstrong\u003e27.9%\u003c\/strong\u003e R\u0026amp;D ratio shows that pipeline development is one of the company's biggest operating uses of cash.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$17.9B\u003c\/strong\u003e R\u0026amp;D expense in 2024\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e27.9%\u003c\/strong\u003e of 2024 revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$64.2B\u003c\/strong\u003e 2024 revenue base\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eClinical trial execution\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eClinical execution is the bridge between R\u0026amp;D spending and approval-ready data. In 2024, Merck \u0026amp; Co., Inc. converted late-stage work into \u003cstrong\u003e2\u003c\/strong\u003e U.S. approvals: sotatercept-csrk and a \u003cstrong\u003e21\u003c\/strong\u003e-valent pneumococcal conjugate vaccine. That means the company's trial engine has to manage enrollment, endpoints, monitoring, and data quality across global sites, because each readout can decide whether a program becomes a commercial product.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e U.S. approvals in 2024\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e21\u003c\/strong\u003e-valent pneumococcal conjugate vaccine\u003c\/li\u003e\n\u003cli\u003esotatercept-csrk\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory output\u003c\/td\u003e\n\u003ctd\u003eYear\u003c\/td\u003e\n\u003ctd\u003eType\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003esotatercept-csrk\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eBiologic approval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e21-valent pneumococcal conjugate vaccine\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eVaccine approval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegulatory approvals and filings\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRegulatory work is a separate activity because approval depends on more than efficacy data. Merck \u0026amp; Co., Inc. has to file clinical evidence, manufacturing data, and safety documentation with regulators such as the FDA, and the 2024 output was \u003cstrong\u003e2\u003c\/strong\u003e approvals. For a Canvas analysis, this is the point where internal science becomes a formal license to sell, so filing quality directly affects launch timing and revenue timing.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal manufacturing and supply\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eManufacturing is a core activity because Merck \u0026amp; Co., Inc. has to supply \u003cstrong\u003e2\u003c\/strong\u003e new approved products from 2024 while keeping its existing portfolio in stock. The work includes process validation, batch release, quality control, packaging, and distribution. For biologics and vaccines, supply execution matters because delays at the plant can slow launches even when trial data are already positive.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e new approvals in 2024 added supply-chain load\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e included both a biologic approval and a \u003cstrong\u003e21\u003c\/strong\u003e-valent vaccine approval\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eBusiness development and M\u0026amp;A\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. uses acquisitions to add assets faster than internal R\u0026amp;D alone can do. In 2024, it announced Harpoon Therapeutics for \u003cstrong\u003e$680M\u003c\/strong\u003e and EyeBio for \u003cstrong\u003e$1.3B\u003c\/strong\u003e upfront plus up to \u003cstrong\u003e$1.7B\u003c\/strong\u003e in milestone payments. Earlier deal values stayed large too: Prometheus Biosciences at \u003cstrong\u003e$10.8B\u003c\/strong\u003e and Imago Biosciences at \u003cstrong\u003e$1.35B\u003c\/strong\u003e. Relative to the \u003cstrong\u003e$17.9B\u003c\/strong\u003e R\u0026amp;D budget, the EyeBio upfront payment was \u003cstrong\u003e7.3%\u003c\/strong\u003e, Harpoon was \u003cstrong\u003e3.8%\u003c\/strong\u003e, Prometheus was \u003cstrong\u003e60.3%\u003c\/strong\u003e, and Imago was \u003cstrong\u003e7.5%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eTransaction\u003c\/td\u003e\n\u003ctd\u003eYear\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eStrategic area\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHarpoon Therapeutics\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e$680M\u003c\/td\u003e\n\u003ctd\u003eOncology pipeline build\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEyeBio upfront\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e$1.3B\u003c\/td\u003e\n\u003ctd\u003eOphthalmology pipeline build\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEyeBio milestones\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eup to $1.7B\u003c\/td\u003e\n\u003ctd\u003eContingent pipeline value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrometheus Biosciences\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003e$10.8B\u003c\/td\u003e\n\u003ctd\u003eImmunology pipeline build\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImago Biosciences\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003e$1.35B\u003c\/td\u003e\n\u003ctd\u003eHematology pipeline build\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eMerck \u0026amp; Co., Inc. - Canvas Business Model: Key Resources\u003c\/h2\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. depended on \u003cstrong\u003e$29.5B\u003c\/strong\u003e Keytruda sales, \u003cstrong\u003e$64.2B\u003c\/strong\u003e total 2024 sales, \u003cstrong\u003e75,000\u003c\/strong\u003e employees, and \u003cstrong\u003e$17.9B\u003c\/strong\u003e in 2024 research and development expense.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$29.5B\u003c\/strong\u003e Keytruda sales in 2024\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$25.0B\u003c\/strong\u003e Keytruda sales in 2023\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.5B\u003c\/strong\u003e year-over-year increase\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e18%\u003c\/strong\u003e year-over-year growth\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e45.9%\u003c\/strong\u003e of \u003cstrong\u003e$64.2B\u003c\/strong\u003e company sales\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e75,000\u003c\/strong\u003e employees worldwide\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeytruda sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$29.5B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeytruda sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$25.0B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2023\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMerck \u0026amp; Co., Inc. sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$64.2B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeytruda share of company sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e45.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e75,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and development expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.9B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and development expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.5B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2023\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eKeytruda franchise\u003c\/strong\u003e: \u003cstrong\u003e$29.5B\u003c\/strong\u003e in 2024 sales, \u003cstrong\u003e$25.0B\u003c\/strong\u003e in 2023 sales, \u003cstrong\u003e$4.5B\u003c\/strong\u003e in absolute growth, and \u003cstrong\u003e18%\u003c\/strong\u003e year-over-year growth.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eGlobal late-stage pipeline\u003c\/strong\u003e: \u003cstrong\u003e$17.9B\u003c\/strong\u003e in research and development expense in 2024, compared with \u003cstrong\u003e$13.5B\u003c\/strong\u003e in 2023, a difference of \u003cstrong\u003e$4.4B\u003c\/strong\u003e and \u003cstrong\u003e32.6%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e75,000-person workforce\u003c\/strong\u003e: \u003cstrong\u003e75,000\u003c\/strong\u003e employees worldwide in 2024, alongside \u003cstrong\u003e$64.2B\u003c\/strong\u003e in sales.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eManufacturing network and research hubs\u003c\/strong\u003e: \u003cstrong\u003e$17.9B\u003c\/strong\u003e in 2024 research and development expense and \u003cstrong\u003e75,000\u003c\/strong\u003e employees supported development, scale-up, and supply.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePatents, AI tools, and data platforms\u003c\/strong\u003e: \u003cstrong\u003e45.9%\u003c\/strong\u003e of 2024 sales came from Keytruda, equal to \u003cstrong\u003e$29.5B\u003c\/strong\u003e, while total 2024 sales were \u003cstrong\u003e$64.2B\u003c\/strong\u003e.\u003c\/p\u003e\u003ch2\u003eMerck \u0026amp; Co., Inc. - Canvas Business Model: Value Propositions\u003c\/h2\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. built its value proposition around \u003cstrong\u003e$25.0B\u003c\/strong\u003e Keytruda sales, \u003cstrong\u003e$8.9B\u003c\/strong\u003e Gardasil 9 sales, \u003cstrong\u003e$5.6B\u003c\/strong\u003e Animal Health revenue, and \u003cstrong\u003e$60.1B\u003c\/strong\u003e total revenue in 2023. Winrevair added a new cardiovascular franchise with a \u003cstrong\u003e40.8\u003c\/strong\u003e-meter treatment effect at \u003cstrong\u003e24\u003c\/strong\u003e weeks in a \u003cstrong\u003e323\u003c\/strong\u003e-patient phase 3 trial.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLeading immuno-oncology therapies\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eKeytruda is the center of Merck's oncology value proposition. It generated \u003cstrong\u003e$25.0B\u003c\/strong\u003e in 2023, which was \u003cstrong\u003e41.6%\u003c\/strong\u003e of Merck's \u003cstrong\u003e$60.1B\u003c\/strong\u003e total revenue. That scale matters because one drug funded nearly half of company sales and gave Merck a large recurring cash base from oncology use across multiple cancers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$25.0B\u003c\/strong\u003e Keytruda revenue in 2023\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e41.6%\u003c\/strong\u003e of Merck's \u003cstrong\u003e$60.1B\u003c\/strong\u003e total revenue\u003c\/li\u003e\n \u003cli\u003ePD-1 immuno-oncology platform\u003c\/li\u003e\n\u003cli\u003eSingle-product revenue scale above \u003cstrong\u003e$20B\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eHigh-margin patent-protected medicines\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMerck's patent-protected medicine value proposition shows up in the gap between total company revenue and its biggest products. After Keytruda's \u003cstrong\u003e$25.0B\u003c\/strong\u003e, Merck still reported \u003cstrong\u003e$35.1B\u003c\/strong\u003e from the rest of the business in 2023. That gives the company a portfolio with multiple protected revenue pools instead of one product only.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eValue proposition\u003c\/th\u003e\n\u003cth\u003e2023 revenue\u003c\/th\u003e\n\u003cth\u003eShare of \u003cstrong\u003e$60.1B\u003c\/strong\u003e\n\u003c\/th\u003e\n\u003cth\u003eNumeric signal\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeytruda\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$25.0B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e41.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e flagship oncology drug\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGardasil 9\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.9B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e9\u003c\/strong\u003e HPV types\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMerck Animal Health\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.6B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5\u003c\/strong\u003e end markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeytruda + Gardasil 9 + Merck Animal Health\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003e$39.5B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e65.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$20.6B\u003c\/strong\u003e remaining company revenue\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eVaccines for major infectious diseases\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMerck's vaccine value proposition is built on multivalent coverage. Gardasil 9 covers \u003cstrong\u003e9\u003c\/strong\u003e HPV types and is indicated for females and males ages \u003cstrong\u003e9\u003c\/strong\u003e through \u003cstrong\u003e45\u003c\/strong\u003e years in the United States. Vaxneuvance is a \u003cstrong\u003e15\u003c\/strong\u003e-valent pneumococcal conjugate vaccine. M-M-R II covers \u003cstrong\u003e3\u003c\/strong\u003e diseases, ProQuad covers \u003cstrong\u003e4\u003c\/strong\u003e diseases, and RotaTeq is a \u003cstrong\u003e5\u003c\/strong\u003e-valent rotavirus vaccine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGardasil 9: \u003cstrong\u003e9\u003c\/strong\u003e HPV types\u003c\/li\u003e\n \u003cli\u003eGardasil 9: ages \u003cstrong\u003e9\u003c\/strong\u003e to \u003cstrong\u003e45\u003c\/strong\u003e\n\u003c\/li\u003e\n \u003cli\u003eVaxneuvance: \u003cstrong\u003e15\u003c\/strong\u003e serotypes\u003c\/li\u003e\n \u003cli\u003eM-M-R II: \u003cstrong\u003e3\u003c\/strong\u003e diseases\u003c\/li\u003e\n\u003cli\u003eProQuad: \u003cstrong\u003e4\u003c\/strong\u003e diseases\u003c\/li\u003e\n\u003cli\u003eRotaTeq: \u003cstrong\u003e5\u003c\/strong\u003e rotavirus types\u003c\/li\u003e\n \u003cli\u003eGardasil 9 revenue in 2023: \u003cstrong\u003e$8.9B\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAnimal health products and services\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMerck Animal Health generated \u003cstrong\u003e$5.6B\u003c\/strong\u003e in 2023, equal to \u003cstrong\u003e9.3%\u003c\/strong\u003e of Merck's \u003cstrong\u003e$60.1B\u003c\/strong\u003e revenue. The segment spans \u003cstrong\u003e5\u003c\/strong\u003e major end markets: cattle, swine, poultry, companion animals, and equine. That mix gives Merck revenue from recurring animal care needs rather than only from human prescription cycles.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$5.6B\u003c\/strong\u003e Merck Animal Health revenue in 2023\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e9.3%\u003c\/strong\u003e of total company revenue\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e5\u003c\/strong\u003e end markets\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e non-human health platform with diversified demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eEmerging cardiovascular and HIV treatments\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWinrevair received FDA approval in \u003cstrong\u003e2024\u003c\/strong\u003e. In the STELLAR trial, the 6-minute walk distance treatment effect was \u003cstrong\u003e40.8\u003c\/strong\u003e meters at \u003cstrong\u003e24\u003c\/strong\u003e weeks in \u003cstrong\u003e323\u003c\/strong\u003e adults. That gives Merck a new specialty franchise outside oncology and vaccines.\u003c\/p\u003e\n\u003cp\u003eMerck's HIV value proposition includes \u003cstrong\u003e2\u003c\/strong\u003e marketed oral products, Pifeltro and Delstrigo. Delstrigo is a \u003cstrong\u003e3\u003c\/strong\u003e-drug single-tablet regimen, and both products are taken \u003cstrong\u003e1\u003c\/strong\u003e time daily. Lower pill burden matters because adherence is tied to treatment success.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWinrevair FDA approval: \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/li\u003e\n \u003cli\u003eSTELLAR trial: \u003cstrong\u003e323\u003c\/strong\u003e adults\u003c\/li\u003e\n \u003cli\u003e6-minute walk distance effect: \u003cstrong\u003e40.8\u003c\/strong\u003e meters\u003c\/li\u003e\n \u003cli\u003eEndpoint timing: \u003cstrong\u003e24\u003c\/strong\u003e weeks\u003c\/li\u003e\n \u003cli\u003eHIV portfolio: \u003cstrong\u003e2\u003c\/strong\u003e marketed oral products\u003c\/li\u003e\n \u003cli\u003eDelstrigo: \u003cstrong\u003e3\u003c\/strong\u003e drugs\u003c\/li\u003e\n\u003cli\u003eOnce-daily dosing: \u003cstrong\u003e1\u003c\/strong\u003e time per day\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eMerck \u0026amp; Co., Inc. - Canvas Business Model: Customer Relationships\u003c\/h2\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. customer relationships were anchored in \u003cstrong\u003e$64.2 billion\u003c\/strong\u003e of 2024 sales, with Keytruda at \u003cstrong\u003e$29.5 billion\u003c\/strong\u003e and Gardasil\/Gardasil 9 at \u003cstrong\u003e$8.6 billion\u003c\/strong\u003e. Those two products alone were \u003cstrong\u003e$38.1 billion\u003c\/strong\u003e, or \u003cstrong\u003e59.3%\u003c\/strong\u003e of total sales.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eRelationship channel\u003c\/th\u003e\n\u003cth\u003eNumeric evidence\u003c\/th\u003e\n\u003cth\u003eBusiness model effect\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysician and hospital engagement\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$29.5 billion\u003c\/strong\u003e Keytruda sales in 2024; dosing of \u003cstrong\u003e200 mg\u003c\/strong\u003e every \u003cstrong\u003e3 weeks\u003c\/strong\u003e or \u003cstrong\u003e400 mg\u003c\/strong\u003e every \u003cstrong\u003e6 weeks\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eRepeated specialist prescribing and infusion-site contact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer and government negotiations\u003c\/td\u003e\n\u003ctd\u003eTotal 2024 sales of \u003cstrong\u003e$64.2 billion\u003c\/strong\u003e; Keytruda share \u003cstrong\u003e45.9%\u003c\/strong\u003e; Gardasil\/Gardasil 9 share \u003cstrong\u003e13.4%\u003c\/strong\u003e; combined \u003cstrong\u003e59.3%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eReimbursement and tender prices move large absolute dollars\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic-sector vaccine procurement\u003c\/td\u003e\n\u003ctd\u003eGardasil\/Gardasil 9 sales of \u003cstrong\u003e$8.6 billion\u003c\/strong\u003e; \u003cstrong\u003e9-valent\u003c\/strong\u003e HPV vaccine; \u003cstrong\u003e2-dose\u003c\/strong\u003e schedule for ages \u003cstrong\u003e9-14\u003c\/strong\u003e; \u003cstrong\u003e3-dose\u003c\/strong\u003e schedule for ages \u003cstrong\u003e15-45\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eNational, regional, and school-based vaccination programs shape demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term patient access programs\u003c\/td\u003e\n\u003ctd\u003e2024 R\u0026amp;D spending of \u003cstrong\u003e$17.9 billion\u003c\/strong\u003e; Keytruda dosing every \u003cstrong\u003e6 weeks\u003c\/strong\u003e; Gardasil 9 schedules of \u003cstrong\u003e2 doses\u003c\/strong\u003e and \u003cstrong\u003e3 doses\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eLonger treatment continuity and fewer clinic visits support adherence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnimal health customer support\u003c\/td\u003e\n\u003ctd\u003eBravecto protection interval of \u003cstrong\u003e12 weeks\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQuarterly follow-up with veterinarians and pet owners\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003ePhysician and hospital engagement: Keytruda at \u003cstrong\u003e$29.5 billion\u003c\/strong\u003e in 2024 meant oncology centers, hospitals, and infusion sites were the main relationship nodes. The \u003cstrong\u003e3-week\u003c\/strong\u003e and \u003cstrong\u003e6-week\u003c\/strong\u003e dosing cadence keeps the customer relationship repeated instead of one-time.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKeytruda contributed \u003cstrong\u003e45.9%\u003c\/strong\u003e of total 2024 sales.\u003c\/li\u003e\n\u003cli\u003eKeytruda dosing used \u003cstrong\u003e200 mg\u003c\/strong\u003e every \u003cstrong\u003e3 weeks\u003c\/strong\u003e or \u003cstrong\u003e400 mg\u003c\/strong\u003e every \u003cstrong\u003e6 weeks\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCombined with Gardasil\/Gardasil 9, these two products accounted for \u003cstrong\u003e59.3%\u003c\/strong\u003e of total sales.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePayer and government negotiations: Merck \u0026amp; Co., Inc. had \u003cstrong\u003e$64.2 billion\u003c\/strong\u003e of 2024 sales, so reimbursement terms and government pricing decisions affected very large dollar amounts. Keytruda and Gardasil\/Gardasil 9 together were \u003cstrong\u003e$38.1 billion\u003c\/strong\u003e, which made payer access a core relationship issue.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKeytruda represented \u003cstrong\u003e45.9%\u003c\/strong\u003e of 2024 sales.\u003c\/li\u003e\n\u003cli\u003eGardasil\/Gardasil 9 represented \u003cstrong\u003e13.4%\u003c\/strong\u003e of 2024 sales.\u003c\/li\u003e\n\u003cli\u003eThe combined share was \u003cstrong\u003e59.3%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePublic-sector vaccine procurement: Gardasil\/Gardasil 9 generated \u003cstrong\u003e$8.6 billion\u003c\/strong\u003e in 2024 sales. The product is \u003cstrong\u003e9-valent\u003c\/strong\u003e, with a \u003cstrong\u003e2-dose\u003c\/strong\u003e schedule for ages \u003cstrong\u003e9-14\u003c\/strong\u003e and a \u003cstrong\u003e3-dose\u003c\/strong\u003e schedule for ages \u003cstrong\u003e15-45\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$8.6 billion\u003c\/strong\u003e of sales came from Gardasil\/Gardasil 9 in 2024.\u003c\/li\u003e\n\u003cli\u003eThe vaccine covers \u003cstrong\u003e9\u003c\/strong\u003e HPV types.\u003c\/li\u003e\n\u003cli\u003eThe age bands were \u003cstrong\u003e9-14\u003c\/strong\u003e and \u003cstrong\u003e15-45\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eLong-term patient access programs: Merck \u0026amp; Co., Inc. reported \u003cstrong\u003e$17.9 billion\u003c\/strong\u003e of R\u0026amp;D spending in 2024. That level of investment supports future labels, longer treatment lifecycles, and more patient touchpoints through dosing intervals of \u003cstrong\u003e6 weeks\u003c\/strong\u003e and \u003cstrong\u003e2-dose\u003c\/strong\u003e or \u003cstrong\u003e3-dose\u003c\/strong\u003e vaccine schedules.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D spending was \u003cstrong\u003e$17.9 billion\u003c\/strong\u003e in 2024.\u003c\/li\u003e\n\u003cli\u003eKeytruda dosing included \u003cstrong\u003e6-week\u003c\/strong\u003e intervals.\u003c\/li\u003e\n\u003cli\u003eGardasil 9 used \u003cstrong\u003e2\u003c\/strong\u003e-dose and \u003cstrong\u003e3\u003c\/strong\u003e-dose schedules.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAnimal health customer support: Bravecto's protection interval of \u003cstrong\u003e12 weeks\u003c\/strong\u003e creates recurring contact with veterinarians and pet owners. That \u003cstrong\u003e12-week\u003c\/strong\u003e cycle turns customer support into a repeat-service relationship instead of a single purchase event.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBravecto protection lasted \u003cstrong\u003e12 weeks\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e12 weeks\u003c\/strong\u003e equals \u003cstrong\u003e4\u003c\/strong\u003e quarterly follow-up points per year.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eMerck \u0026amp; Co., Inc. - Canvas Business Model: Channels\u003c\/h2\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. built its channel model on \u003cstrong\u003e$64.2 billion\u003c\/strong\u003e in 2024 net sales, approximately \u003cstrong\u003e73,000\u003c\/strong\u003e employees worldwide, and sales in more than \u003cstrong\u003e140\u003c\/strong\u003e countries.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$64.2 billion\u003c\/strong\u003e 2024 net sales\u003c\/li\u003e\n\u003cli\u003eApproximately \u003cstrong\u003e73,000\u003c\/strong\u003e employees worldwide\u003c\/li\u003e\n\u003cli\u003eMore than \u003cstrong\u003e140\u003c\/strong\u003e countries\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e large U.S. wholesalers in the prescription market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eChannel\u003c\/td\u003e\n\u003ctd\u003eReal-life numeric anchor\u003c\/td\u003e\n\u003ctd\u003eChannel function\u003c\/td\u003e\n\u003ctd\u003eBusiness impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal pharmaceutical sales force\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e73,000\u003c\/strong\u003e employees worldwide\u003c\/td\u003e\n\u003ctd\u003eDirect field coverage\u003c\/td\u003e\n\u003ctd\u003eSupports prescribers, hospital accounts, and payer access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals and specialty pharmacies\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$64.2 billion\u003c\/strong\u003e 2024 net sales\u003c\/td\u003e\n\u003ctd\u003eSpecialty access\u003c\/td\u003e\n\u003ctd\u003eMoves high-touch products through controlled channels\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic health and tender channels\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e140\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eGovernment procurement\u003c\/td\u003e\n\u003ctd\u003eNational programs, tenders, and immunization systems\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesale and distributor networks\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e large U.S. wholesalers\u003c\/td\u003e\n\u003ctd\u003eBulk replenishment\u003c\/td\u003e\n\u003ctd\u003eNational inventory movement and pharmacy supply\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMSD international commercial network\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e140\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eLocal affiliates and partners\u003c\/td\u003e\n\u003ctd\u003eCountry pricing, reimbursement, and access execution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003eGlobal pharmaceutical sales force uses local field teams to reach hospitals, physician groups, and payer decision makers. At a business scale of \u003cstrong\u003e$64.2 billion\u003c\/strong\u003e, direct selling matters because access delays can move large amounts of revenue across quarters.\u003c\/p\u003e\n\u003cp\u003eHospitals and specialty pharmacies are the right channel for products that need prior authorization, infusion-site administration, cold-chain handling, or patient onboarding. This channel usually carries more administrative steps than retail pharmacy, so speed of approval and refill persistence matter as much as order volume.\u003c\/p\u003e\n\u003cp\u003ePublic health and tender channels become more important when the buyer is a government, ministry, or national program instead of an individual prescriber. Merck's reach across more than \u003cstrong\u003e140\u003c\/strong\u003e countries makes tender pricing, supply reliability, and regulatory compliance central to channel performance.\u003c\/p\u003e\n\u003cp\u003eWholesale and distributor networks are the main physical bridge between manufacturer and pharmacy in the U.S. prescription market. The concentration around \u003cstrong\u003e3\u003c\/strong\u003e large national wholesalers means Merck depends on a small number of counterparties for inventory flow and accounts receivable discipline.\u003c\/p\u003e\n\u003cp\u003eMSD international commercial network gives Merck local execution outside the U.S. across more than \u003cstrong\u003e140\u003c\/strong\u003e countries. That network matters because pricing, reimbursement, tax, and tender rules change country by country, so one global product portfolio still needs local channel control.\u003c\/p\u003e\n\u003ch2\u003eMerck \u0026amp; Co., Inc. - Canvas Business Model: Customer Segments\u003c\/h2\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. reported \u003cstrong\u003e$64.2 billion\u003c\/strong\u003e in 2024 revenue. The late-2025 customer base centers on \u003cstrong\u003e5\u003c\/strong\u003e groups: oncology, cardiovascular and specialty care, vaccines, governments and public health systems, and Animal Health.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCustomer segment\u003c\/th\u003e\n\u003cth\u003eTypical buyer or user\u003c\/th\u003e\n\u003cth\u003eNumeric anchor\u003c\/th\u003e\n\u003cth\u003eCustomer logic\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology patients and providers\u003c\/td\u003e\n\u003ctd\u003eOncologists, cancer centers, hospitals, infusion sites\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$29.5 billion\u003c\/strong\u003e Keytruda sales in 2024\u003c\/td\u003e\n\u003ctd\u003eHigh-acuity treatment demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiovascular and specialty care patients\u003c\/td\u003e\n\u003ctd\u003eAdult specialty-care prescribers and treatment centers\u003c\/td\u003e\n\u003ctd\u003eAdult-only customer base; 2024 launch year for the main new therapy class\u003c\/td\u003e\n\u003ctd\u003eSpecialist-led prescribing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdult and pediatric vaccine recipients\u003c\/td\u003e\n\u003ctd\u003eChildren, adolescents, adults, parents, caregivers\u003c\/td\u003e\n\u003ctd\u003eGardasil 9 ages \u003cstrong\u003e9\u003c\/strong\u003e through \u003cstrong\u003e45\u003c\/strong\u003e; Capvaxive \u003cstrong\u003e18\u003c\/strong\u003e years and older; M-M-R II and Varivax \u003cstrong\u003e12\u003c\/strong\u003e months and older\u003c\/td\u003e\n\u003ctd\u003eAge-based immunization demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernments and public health systems\u003c\/td\u003e\n\u003ctd\u003eNational immunization programs, public hospitals, procurement agencies\u003c\/td\u003e\n\u003ctd\u003ePublic schedules tied to \u003cstrong\u003e12\u003c\/strong\u003e months, \u003cstrong\u003e9\u003c\/strong\u003e years, and \u003cstrong\u003e18\u003c\/strong\u003e years and older\u003c\/td\u003e\n\u003ctd\u003eBulk purchasing and schedule-based demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLivestock and companion animal owners\u003c\/td\u003e\n\u003ctd\u003eVeterinarians, livestock producers, pet owners\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$6.1 billion\u003c\/strong\u003e Animal Health sales in 2024; \u003cstrong\u003e2\u003c\/strong\u003e end markets\u003c\/td\u003e\n\u003ctd\u003eRecurring prevention and treatment use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOncology patients and providers\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eKeytruda generated \u003cstrong\u003e$29.5 billion\u003c\/strong\u003e in 2024, so oncology is the largest and most valuable customer segment for Merck \u0026amp; Co., Inc. The buyer is usually a hospital, oncology clinic, or physician group, while the end user is a cancer patient. The scale of this segment makes reimbursement, guideline placement, and specialist prescribing central to revenue stability.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCardiovascular and specialty care patients\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis segment is narrower than oncology because it is concentrated in adults and specialist prescribers. The main late-2025 anchor is a 2024 launch in pulmonary arterial hypertension, which keeps demand tied to specialty centers rather than mass-market prescribing. That makes the segment smaller in patient count but important in showing Merck \u0026amp; Co., Inc. is adding adult specialty therapy alongside oncology.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAdult and pediatric vaccine recipients\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVaccine demand comes from multiple age bands. Gardasil 9 covers ages \u003cstrong\u003e9\u003c\/strong\u003e through \u003cstrong\u003e45\u003c\/strong\u003e, Capvaxive covers adults \u003cstrong\u003e18\u003c\/strong\u003e years and older, and M-M-R II and Varivax reach patients starting at \u003cstrong\u003e12\u003c\/strong\u003e months. Merck \u0026amp; Co., Inc. recorded \u003cstrong\u003e$8.6 billion\u003c\/strong\u003e in Gardasil franchise sales in 2024, so this segment is both broad and financially material.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e9\u003c\/strong\u003e through \u003cstrong\u003e45\u003c\/strong\u003e: adolescent and adult HPV vaccination demand\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e18\u003c\/strong\u003e years and older: adult pneumococcal vaccination demand\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e12\u003c\/strong\u003e months and older: pediatric measles, mumps, rubella, and varicella demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eGovernments and public health systems\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePublic buyers matter because vaccines move through annual and multi-year procurement programs, not only through individual retail sales. The relevant numeric gates are \u003cstrong\u003e12\u003c\/strong\u003e months, \u003cstrong\u003e9\u003c\/strong\u003e years, and \u003cstrong\u003e18\u003c\/strong\u003e years and older, which align with school entry, adolescent catch-up, and adult protection schedules. This segment is important because large public orders can shift volume quickly across a full country or region.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLivestock and companion animal owners\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. reported \u003cstrong\u003e$6.1 billion\u003c\/strong\u003e of Animal Health sales in 2024, split across \u003cstrong\u003e2\u003c\/strong\u003e end markets: livestock and companion animals. That split matters because livestock demand is driven by herd economics and biosecurity, while companion-animal demand is driven by pet ownership, preventive care, and repeat purchases through veterinarians and distributors.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e end markets: livestock and companion animals\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$6.1 billion\u003c\/strong\u003e: 2024 Animal Health sales\u003c\/li\u003e\n\u003cli\u003eVeterinarians as the main prescribing and dispensing channel\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eMerck \u0026amp; Co., Inc. - Canvas Business Model: Cost Structure\u003c\/h2\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. reported \u003cstrong\u003e$64.2 billion\u003c\/strong\u003e of revenue in 2024, with \u003cstrong\u003e$17.9 billion\u003c\/strong\u003e in research and development and \u003cstrong\u003e$9.7 billion\u003c\/strong\u003e in SG\u0026amp;A; R\u0026amp;D was \u003cstrong\u003e27.9%\u003c\/strong\u003e of revenue and SG\u0026amp;A was \u003cstrong\u003e15.1%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCost item\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAmount\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eYear\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eRevenue base\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eShare of revenue\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$64.2 billion\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e$64.2 billion\u003c\/td\u003e\n\u003ctd\u003e100.0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and development\u003c\/td\u003e\n\u003ctd\u003e$17.9 billion\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e$64.2 billion\u003c\/td\u003e\n\u003ctd\u003e27.9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$9.7 billion\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e$64.2 billion\u003c\/td\u003e\n\u003ctd\u003e15.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrometheus Biosciences acquired IPR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$10.8 billion\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003e$60.1 billion\u003c\/td\u003e\n\u003ctd\u003e18.0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEyeBio upfront payment\u003c\/td\u003e\n\u003ctd\u003e$1.3 billion\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e$64.2 billion\u003c\/td\u003e\n\u003ctd\u003e2.0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eResearch and development expense\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMerck's \u003cstrong\u003e$17.9 billion\u003c\/strong\u003e R\u0026amp;D bill in 2024 is the main fixed cost tied to pipeline growth. At \u003cstrong\u003e27.9%\u003c\/strong\u003e of revenue, it is the single biggest operating cost bucket in the canvas model and it is the line most exposed to trial starts, new programs, and licensing activity.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eClinical trial and regulatory costs\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eClinical trial, submission, and regulatory work sit inside the \u003cstrong\u003e$17.9 billion\u003c\/strong\u003e R\u0026amp;D figure. Merck did not publish a separate dollar line for these costs, so the relevant number for this bucket is the full R\u0026amp;D spend.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$17.9 billion\u003c\/strong\u003e covers trial design, patient enrollment, site payments, data work, and filing activity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$10.8 billion\u003c\/strong\u003e of Prometheus acquired IPR\u0026amp;D in 2023 shows how development spending can jump from one transaction.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1.3 billion\u003c\/strong\u003e for EyeBio in 2024 shows the same pattern at a smaller scale.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eManufacturing and supply chain costs\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eManufacturing, packaging, quality control, freight, and royalty-linked production costs are embedded in cost of sales. Using \u003cstrong\u003e$64.2 billion\u003c\/strong\u003e of revenue, every \u003cstrong\u003e1%\u003c\/strong\u003e move in sales-level cost structure equals about \u003cstrong\u003e$642 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSG\u0026amp;A and commercial spending\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMerck reported \u003cstrong\u003e$9.7 billion\u003c\/strong\u003e of SG\u0026amp;A in 2024, equal to \u003cstrong\u003e15.1%\u003c\/strong\u003e of revenue. This bucket covers the sales force, marketing, medical affairs, corporate functions, and other commercial overhead.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$9.7 billion\u003c\/strong\u003e in SG\u0026amp;A was \u003cstrong\u003e$8.2 billion\u003c\/strong\u003e lower than R\u0026amp;D.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$9.7 billion\u003c\/strong\u003e was about \u003cstrong\u003e54.2%\u003c\/strong\u003e of the \u003cstrong\u003e$17.9 billion\u003c\/strong\u003e R\u0026amp;D line.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAcquisition and integration charges\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMerck recorded a \u003cstrong\u003e$10.8 billion\u003c\/strong\u003e acquired in-process research and development charge for Prometheus Biosciences in 2023.\u003c\/p\u003e\n\u003cp\u003eMerck also paid \u003cstrong\u003e$1.3 billion\u003c\/strong\u003e upfront for EyeBio in 2024.\u003c\/p\u003e\n\u003cp\u003eThese amounts can move reported R\u0026amp;D by billions in a single period and are a major part of the cost structure when Merck pursues external pipeline expansion.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eAcquisition-related item\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAmount\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eYear\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eShare of revenue\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrometheus Biosciences acquired IPR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$10.8 billion\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003e18.0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEyeBio upfront payment\u003c\/td\u003e\n\u003ctd\u003e$1.3 billion\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e2.0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\u003ch2\u003eMerck \u0026amp; Co., Inc. - Canvas Business Model: Revenue Streams\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$64.2B\u003c\/strong\u003e total sales in 2024, with \u003cstrong\u003e$62.5B\u003c\/strong\u003e product sales, \u003cstrong\u003e$29.5B\u003c\/strong\u003e Keytruda sales, \u003cstrong\u003e$8.6B\u003c\/strong\u003e Gardasil\/Gardasil 9 sales, \u003cstrong\u003e$6.1B\u003c\/strong\u003e Animal Health sales, and \u003cstrong\u003e$1.7B\u003c\/strong\u003e alliance and license revenue.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eRevenue stream\u003c\/th\u003e\n\u003cth\u003e2024 amount\u003c\/th\u003e\n\u003cth\u003eShare of $64.2B sales\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescription pharmaceutical sales\u003c\/td\u003e\n\u003ctd\u003e$62.5B\u003c\/td\u003e\n\u003ctd\u003e97.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeytruda and oncology revenue\u003c\/td\u003e\n\u003ctd\u003e$29.5B\u003c\/td\u003e\n\u003ctd\u003e46.0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVaccine sales\u003c\/td\u003e\n\u003ctd\u003e$8.6B\u003c\/td\u003e\n\u003ctd\u003e13.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnimal health sales\u003c\/td\u003e\n\u003ctd\u003e$6.1B\u003c\/td\u003e\n\u003ctd\u003e9.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing and milestone-related income\u003c\/td\u003e\n\u003ctd\u003e$1.7B\u003c\/td\u003e\n\u003ctd\u003e2.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003ePrescription pharmaceutical sales\u003c\/strong\u003e: \u003cstrong\u003e$62.5B\u003c\/strong\u003e in 2024 product sales. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$29.5B\u003c\/strong\u003e Keytruda\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$8.6B\u003c\/strong\u003e Gardasil\/Gardasil 9\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eKeytruda and oncology revenue\u003c\/strong\u003e: \u003cstrong\u003e$29.5B\u003c\/strong\u003e in 2024, equal to \u003cstrong\u003e46.0%\u003c\/strong\u003e of total sales.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eVaccine sales\u003c\/strong\u003e: \u003cstrong\u003e$8.6B\u003c\/strong\u003e from Gardasil\/Gardasil 9 in 2024, equal to \u003cstrong\u003e13.4%\u003c\/strong\u003e of total sales.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAnimal health sales\u003c\/strong\u003e: \u003cstrong\u003e$6.1B\u003c\/strong\u003e in 2024, equal to \u003cstrong\u003e9.5%\u003c\/strong\u003e of total sales.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLicensing and milestone-related income\u003c\/strong\u003e: \u003cstrong\u003e$1.7B\u003c\/strong\u003e of alliance and license revenue in 2024, equal to \u003cstrong\u003e2.6%\u003c\/strong\u003e of total sales.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44601613418645,"sku":"mrk-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/mrk-business-model-canvas.png?v=1740194556","url":"https:\/\/dcf-model.com\/es\/products\/mrk-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}